Sign in

HIK on London Stock Exchange

Hikma Pharmaceuticals

Logo: Hikma pharma, CC BY-SA 4.0, via Wikimedia Commons4

British multinational pharmaceutical company

Hikma Pharmaceuticals plc is a British multinational pharmaceutical company with headquarters in London, UK that manufactures non-branded generic and in-licensed pharmaceutical products. It was founded by Samih Darwazah in Amman, Jordan in 1978. It is listed on the London Stock Exchange and is a constituent of the FTSE 250 Index.2 It was founded by SEAZ.1 Its chief executive is Said Darwazah.1 Wikipedia text CC BY-SA 4.0

Price unavailable

Last updated Oct 21, 2026.

Overview

1978Founded1

Compare with another stock.

  • TickerHIK on London Stock Exchange1
  • Industrypharmaceutical industry1
  • HeadquartersLondon1
  • Founded inJordan1
  • Websitewww.hikma.com
  • Legal formpublic limited company1
  • LEI549300BNS685UXH4JI753
  • StatusActive3
  • LEI statusIssued and current3
  • Registered address1 New Burlington Place, W1S 2HR London, United Kingdom3
  • Registered withCompanies House, 055579343

See how the biggest companies compare on our leaderboards

Hikma Pharmaceuticals plc is a British multinational pharmaceutical company with headquarters in London, UK that manufactures non-branded generic and in-licensed pharmaceutical products. It was founded by Samih Darwazah in Amman, Jordan in 1978. It is listed on the London Stock Exchange and is a constituent of the FTSE 250 Index.2

Corporate structure

Hikma Pharmaceuticals sits at the top of its group. 3 entities, 2 countries on record. Switch between the flow chart and the network, and select any entity to see its details.

  • Hikma Pharmaceuticals London, United Kingdom

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); subsidiaries, stakes and holdings from Wikidata (CC0). Each entity in the chart links to its source.

The story

Founded by SEAZ in 1978, in Jordan.1

The company was founded in 1978 by Samih Darwazah in Amman, Jordan. In August 1996 it became the first Arab company to export pharmaceutical products to the United States. It was first listed on the London Stock Exchange in 2005. Acquisitions in the mid-2000s include Instituto Biochimico Pavese Pharma in Italy in 2005 and Jazeera Pharmaceutical Industries in Saudi Arabia in 2006. In 2007 the company went on to buy APM in Jordan, Alkan Pharma in Egypt, APM and Al Jazeera Pharma in Saudi Arabia, Thymoorgan in Germany, and Ribosepharm in Germany. It started to acquire Baxter Healthcare Corporation's US generic injectables business, Multi-Source Injectables or MSI, and completed the transaction in May 2011.

In October 2011, Hikma Pharmaceuticals entered the Moroccan market through the acquisition of Promopharm, the ninth largest pharmaceutical manufacturer in Morocco. Hikma also inaugurated the Al Dar Al Arabia Pharmaceutical Manufacturing Company in Algeria in 2011. The Algerian pharmaceutical company is Hikma's second venture in Algeria after Hikma Pharma Algeria.

In 2011 the company won the ICSA / Hermes Transparency in Governance Award for the best audit disclosure for a FTSE 250 company.

Hikma expanded its existing presence in the Egyptian market through the acquisition of the Egyptian Company for Pharmaceuticals and Chemical Industries (EPCI) in 2012. In September 2013, Hikma announced expansion into Sub-Saharan Africa with a 50:50 joint venture agreement with MIDROC Pharmaceuticals Limited, to enter the Ethiopian pharmaceutical market.

On 28 May 2014, Hikma Pharmaceuticals agreed to acquire assets from the U.S. generic injectable drugs business of Germany's Boehringer Ingelheim for up to $300 million, boosting its presence in the injected medicine market.

In June 2020, Boehringer announced it would sell off part of its stake in London-listed Hikma Pharmaceuticals (28 million out of a 40 million share holding) for around $800 million.

From Wikipedia’s article on Hikma Pharmaceuticals, shared under CC BY-SA 4.0.5

Leadership

Who has led Hikma Pharmaceuticals, and when. Pick a name to see everywhere that person has worked.

Chair

  1. Said Darwazah2014–now
19801990200020102020

Products and brands

  • amoxicillin/clavulanic acid

Listed on Wikidata.1

Operations

Hikma Pharmaceutical's operations span 29 manufacturing plants in 10 countries: United States, Portugal, Italy, Jordan, Saudi Arabia, Algeria, Germany, Egypt, Morocco, and Tunisia.

Business segments

Branded

Hikma's branded business segment comprises the development and sales of branded generics and in-licensed patented products in the MENA region. Hikma has 499 products in 1,256 dosage strengths. Top products include Actos, Amoclan, Blopress, Omnicef, Prograf, and Suprax.

Injectables

Hikma sells specialized injectable products in the US, Europe and MENA including argatroban, fentanyl, phenylephrine, robaxin, and iron gluconate. The company sells 200 products in 379 dosage forms and strengths.

Generics

Hikma's oral generic products are sold in the US and include such products as amoxicillin, cephalexin, doxycycline, methocarbamol, and prednisone.

From Wikipedia’s article on Hikma Pharmaceuticals, shared under CC BY-SA 4.0.5

Subsidiaries and ownership

Subsidiaries

From Wikidata.1

Timeline

  1. 2005Went public Listed on London Stock Exchange1
  2. 1978Founded Founded in Jordan1

Calendar

Drug trials and FDA: recently

  1. Oct 29, 2025FDA approval FDA approved Enoby (denosumab-qbde), a biologic (BLA 761439).6
  2. Sep 26, 2025FDA approval FDA approved Enoby (denosumab-qbde), a biologic (BLA 761439).7
  3. Aug 25, 2025FDA approved a new use FDA approved an efficacy supplement for Kloxxado (naloxone hydrochloride), a new use or patient group (NDA 212045, supplement 5).8
  4. Jul 16, 2025FDA approved a new use FDA approved an efficacy supplement for Robinul (glycopyrrolate), a new use or patient group (NDA 017558, supplement 68).9
  5. Jun 27, 2025FDA approved a new use FDA approved an efficacy supplement for Tyzavan (vancomycin hydrochloride), a new use or patient group (NDA 211962, supplement 17).10

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). Trials from ClinicalTrials.gov, as the sponsor registered them (expected dates are the sponsor's own and often move); approvals and advisory committee meetings from the FDA. The FDA does not publish its decision (PDUFA) dates. The full markets calendar

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10